Please ensure Javascript is enabled for purposes of website accessibility

Here's Why GenMark Diagnostics Is Rising Today

By Brian Feroldi - Mar 11, 2020 at 12:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Traders are bidding up the stock in response to the submission of a regulatory filing.

What happened

Shares of GenMark Diagnostics (GNMK), a company focused on molecular tests, rose as much as 30% in early morning trading on Wednesday. A lot of the early gains have since been erased, but the stock was still up about 14% as of 12:05 p.m. EDT.

So what

Today's rally is a response to the news that GenMark submitted its ePlex SARS-CoV-2 Test to the Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA). Management also noted that Research Use Only (RUO) versions of its tests were sent out last week to some of its customers for validation. 

Scientist in a lab looking through a microscope.

Image source: Getty Images.

If the ePlex goes on to receive regulatory approval, it could be used by clinical laboratories to test for COVID-19, which is better known as the coronavirus.

Commenting on the submission, GenMark's interim CEO Scott Mendel stated:

Our priority was to help our customers address this global health emergency. We leveraged our adaptable and easy-to-use ePlex platform to quickly design and manufacture a test to accurately detect this highly contagious virus in clinical samples. EUA submission in just over a week from the initial RUO shipments of our ePlex test is a critical step to enable our customers to rapidly detect and possibly prevent the spread of the COVID-19 virus.

Now what

It's great to see that GenMark was able to respond so rapidly to the coronavirus outbreak, but it's important to remember that it isn't the only testing game in town. Companies such as Co-Diagnostics, Danaher, and Quest Diagnostics have also announced plans to bring a coronavirus test to market as soon as possible.

Then again, near-term demand for coronavirus tests is likely to be very high, so GenMark will probably do well even if it finds itself squaring off against a number of competitors.

With the coronavirus making headlines every day, it's likely that every healthcare stock with a link to the disease is going to remain volatile. Investors need to mentally prepare themselves for a bumpy ride. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GenMark Diagnostics, Inc. Stock Quote
GenMark Diagnostics, Inc.
GNMK
Danaher Corporation Stock Quote
Danaher Corporation
DHR
$253.53 (0.00%) $0.01
Quest Diagnostics Incorporated Stock Quote
Quest Diagnostics Incorporated
DGX
$134.58 (1.20%) $1.60
Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
CODX
$5.87 (4.63%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
311%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.